Translation Support for QARA / PRRC and Audit-Ready Documentation

QARA and PRRC professionals are responsible for ensuring multilingual documentation supports regulatory compliance, risk management, traceability and audit readiness. Controlled translation workflows reduce inconsistency across IFUs, labels, technical files and submissions, support terminology consistency aligned with MDR/IVDR, and provide structured evidence through signed translation certificates. They also help manage translation risk across product families and markets. The workflow does not replace QARA or PRRC ownership of regulatory and compliance decisions, but provides a defensible language operations layer that fits inside QMS documentation processes.

MDR translation compliance refers to translation expectations arising from Regulation (EU) 2017/745, including language requirements for IFUs, labels, SSCPs, regulatory submissions and other documentation. The MDR does not prescribe a single translation procedure, but expects manufacturers to demonstrate control over the translation process inside their QMS. EU MDR language requirements vary by market, device class and intended users. AbroadLink supports MDR translation compliance with risk-based workflows, MDR/IVDR-aligned terminology and traceable evidence, but final compliance assessment rests with the manufacturer, notified body and competent authorities.

EU MDR language requirements affect which documents must be translated, into which languages and for which intended users. Member States define national language rules for IFUs, labelling, implant cards, patient-facing materials and professional information. The exact requirements depend on the device, intended users, target markets and the manufacturer's regulatory strategy. QARA and PRRC teams typically map these requirements against the product portfolio. AbroadLink supports the resulting translation activities with controlled workflows and traceable evidence, while the language strategy itself remains a regulatory decision owned by the manufacturer's internal and external advisors.

IVDR translation compliance refers to translation expectations arising from Regulation (EU) 2017/746 for in vitro diagnostic medical devices. It covers IFUs, labels, performance evaluation reports, submissions and other regulated documentation. Like MDR, IVDR expects manufacturers to demonstrate control over translation inside their QMS and to apply translations that fit each device class, intended user and market. AbroadLink supports IVDR translation compliance with IVD-aware linguists, MDR/IVDR-aligned terminology and traceable CertLink evidence, while compliance decisions remain with the manufacturer, notified body and competent authorities.

Audit-ready translations are multilingual deliverables supported by structured evidence that can be presented during audits, notified body reviews or competent authority inspections. Typical elements include supplier ISO certificates, qualified translator profiles, signed translation certificates, revision reports and clear traceability across versions and languages. AbroadLink delivers audit-ready translations through controlled workflows, ISO-based processes and CertLink-supported certificate access. Audit-ready translations support QARA and PRRC work but do not, by themselves, guarantee audit success, notified body acceptance or regulatory approval, which depend on broader QMS, design and regulatory considerations owned by the client.

Translation traceability supports QARA and PRRC by documenting what was translated, by whom, when and using which resources. AbroadLink provides traceability through signed translation certificates identifying documents, project codes, translators and AI models used, accessible through CertLink. Combined with supplier ISO certificates, revision reports and version control, this evidence supports notified body interactions, internal audits and ongoing translation governance. Translation traceability complements your QMS but does not replace document control, change management or regulatory decisions, which remain owned by your internal QARA, PRRC and Regulatory Affairs teams.

Yes, in a controlled way. Through aiHubLink, AbroadLink offers custom AI pre-translation that uses client terminology and legacy translations as references. The AI output is fully reviewed and validated by qualified medical linguists under ISO 9001, ISO 17100 and ISO 13485-based processes. The AI model used is identified on the signed translation certificate. For safety-related, patient-facing or compliance-sensitive content, AI is used cautiously and only when suitable, with documented governance. The decision to use AI-assisted workflows is agreed in advance with the client.

No. Translation services, risk-based workflows, AI-assisted translation, linguistic risk assessment, CertLink certificates and translation governance support help QARA and PRRC teams manage multilingual documentation under controlled processes. However, they do not guarantee MDR compliance, IVDR compliance, notified body acceptance, competent authority acceptance, QMS acceptance, audit success, safe use, patient understanding, product approval, CE marking, market access or business outcomes. These depend on device design, clinical evidence, regulatory strategy, QMS overall design and the assessments of notified bodies, competent authorities and certification bodies, which remain the responsibility of the manufacturer.